Clinical trials of Kazakhstani QazCovid-in vaccine against the COVID-19 virus developed by the Scientific Research Institute for Biological Safety Problems have started, the Ministry of Education and Science reports.
Adult volunteers aged 18-50 years old will be involved in the clinical trials. Phase 1 trials will define the vaccine’s safety on 44 volunteers free of COVID-19 and antibodies. The second phase is set to assess immunogenicity with the involvement of 22 volunteers. A total of 688 applications have been submitted by citizens to take part in the clinical trials.
The vaccine’s clinical trials will be conducted at the Health Ministry’s National Scientific Center of Phthisiopulmonology and Center for Clinical Medicine and Research LLP. (Kazinform/Business World Magazine)
YOUR ADV. here FREE